6,602 Shares in DaVita Inc. (NYSE:DVA) Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,602 shares of the company's stock, valued at approximately $1,010,000.

Other large investors have also recently bought and sold shares of the company. United Capital Financial Advisors LLC raised its stake in shares of DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after purchasing an additional 62 shares during the last quarter. Freedom Investment Management Inc. grew its position in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after purchasing an additional 62 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of DaVita by 2.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock worth $531,000 after purchasing an additional 69 shares in the last quarter. UMB Bank n.a. raised its position in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after purchasing an additional 76 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in DaVita by 8.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock valued at $148,000 after buying an additional 79 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of recent research reports. Truist Financial lowered their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $164.50.

DaVita Price Performance

DaVita stock traded down $0.13 during trading hours on Wednesday, hitting $140.41. 361,232 shares of the company traded hands, compared to its average volume of 808,987. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60. The firm has a market cap of $10.60 billion, a P/E ratio of 13.91, a P/E/G ratio of 0.99 and a beta of 1.11. The firm's 50-day simple moving average is $140.24 and its two-hundred day simple moving average is $148.73. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The business had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the prior year, the business posted $2.26 earnings per share. DaVita's revenue was up 5.0% compared to the same quarter last year. As a group, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.